Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
In this week’s Pathways Picks: AdvaMed tries to set AI policy directions; leaked Trump budget documents suggest limited damage to FDA device program; Makary suggests steps to limit company involvement in advisory panels; China formalizes Green Channel and Priority Approval procedures; UK adopts robotic surgery, and more.
Insulet and Tandem Diabetes Care now have FDA clearance to market their automated insulin delivery systems on-label in the US for type 2 diabetes, and more—including Medtronic, Beta Bionics, and Sequel Med Tech—are likely to follow, ushering in a new era of growth and innovation in the insulin pump industry.
The upswing for Medicare New Technology Add-On Payments continues. Excerpted from Pathways’ Picks April 16: New Tech Payments, China Classifications, Notified Body Positions, and More.